Elucidation of molecular mechanism of neuronal cell death in spinal and bulbar muscular atrophy
Elucidation of molecular mechanism of neuronal cell death in spinal and bulbar muscular atrophy
批准号:
12210010
负责人:
SOBUE Gen
金额:
$69.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Spinal and bulbar muscular atrophy (SBMA) is an adult-onset motor neuron disease affecting only males. The molecular basis of SBMA is the expansion of a trinucleotide CAG repeat in the first exon of the androgen receptor (AR) gene, which encodes the polyglutamine (polyQ) tract. The length of CAG repeat correlates with the severity of SBMA. Immunohistochemical analysis of autopsied specimen demonstrates that diffuse accumulation of mutant AR in the nuclei of spinal motor neurons is a fundamental neuropathological feature of SBMA, extent of which closely relates to CAG repeat length. Thus, diffuse nuclear accumulation of mutant AR is likely crucial pathogenic step in SBMA. We generated two mouse models of SBMA. Among these, a transgenic mouse model carrying full-length AR containing 97 CAGs driven by a chicken (3-actin promoter shows progressive motor impairment and nuclear accumulation of mutant AR. These neurological phenotypes were devastating in male mice, but not observed or far less severe in the females. Surgical castration dramatically prevented the phenotypic expression in the male Tg mice by diminishing the nuclear accumulation of mutant AR. In contrast, the female Tg mice demonstrated striking deterioration of symptoms by testosterone administration. Leuprorelin, an LHRH agonist that reduces testosterone release from the testis, suppressed nuclear accumulation of mutant AR, leading to rescue of motor dysfunction in the male SBMA mice. Our studies have also indicated several candidates of therapeutics for SBMA. Genetic overexpression of heat shock protein (HSP) ameliorates neurodegeneration by improving conformational alteration of mutant AR in the mouse model of SBMA. Oral administration of sodium butyrate, a histone deacetylase inhibitor, resulted in improvement of neurological dysfunction in the SBMA mouse model, al though its therapeutic effects were seen in a narrow dose range.
期刊论文(180)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1093/hmg/9.14.2197
发表时间:
2000-09-01
期刊:
HUMAN MOLECULAR GENETICS
影响因子:
3.5
作者:
[McCampbell, A, Taylor, JP, Fischbeck, KH]
通讯作者:
Fischbeck, KH
Takeuchi H: "Immunoglobulin therapy for idiopathic chronic sensory ataxic neuropathy."Neurology. 54. 1008-1010 (2000)
Takeuchi H:“免疫球蛋白治疗特发性慢性感觉共济失调神经病。”神经病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Watanabe H: "Differential somatic CAG repeat instability in variable brain cell lineage in dentatorubral pallidoluysian atrophy (DRPLA): a laser-captured microdissection (LCM)-based analysis."Hum.Genet.. 107. 452-457 (2000)
Watanabe H:“齿状核红斑苍白卢伊萎缩症 (DRPLA) 中可变脑细胞谱系的差异体细胞 CAG 重复不稳定性:基于激光捕获显微切割 (LCM) 的分析。”Hum.Genet.. 107. 452-457 (2000)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Dorfin prevents cell death by reducing mitochondrial localiaing mutant superoxide dismutase 1 in a neuronal cell model of familial amyotrophic lateral sclerosis.
在家族性肌萎缩侧索硬化症的神经元细胞模型中,Dorfin 通过减少线粒体定位突变型超氧化物歧化酶 1 来防止细胞死亡。
DOI:
--
发表时间:
2004
期刊:
J Neurochem 89
影响因子:
--
作者:
[Takehara, K., et al., Takeuchi H]
通讯作者:
Takeuchi H
Leuprorelin rescue polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy
亮丙瑞林拯救脊髓和延髓肌萎缩转基因小鼠模型中的多谷氨酰胺依赖性表型
DOI:
--
发表时间:
2003
期刊:
Nature Medicine 9(6)
影响因子:
--
作者:
[Mori, H., Mishina, M., Yoshida T et al., Hishikawa N, Katsuno M]
通讯作者:
Katsuno M
共 80 条
Therapeutic strategy of neurodegenerative disease using microRNA
-
批准号:25670418
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2013
-
负责人:SOBUE Gen
-
依托单位:
Identification of therapeutic targets for ALS by screening for TDP-43 and FUS associated molecules
-
批准号:23659452
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:SOBUE Gen
-
依托单位:
Development of Molecular Targeted Disease Modifying Therapy for Polyglutamine Diseases
-
批准号:21229011
-
项目类别:Grant-in-Aid for Scientific Research (S)
-
资助金额:$101.59万
-
财政年份:2009
-
负责人:SOBUE Gen
-
依托单位:
Pathogenesis-based therapy development for polyglutamine diseases
-
批准号:19209033
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$32.61万
-
财政年份:2007
-
负责人:SOBUE Gen
-
依托单位:
Treatment of polyglutamine disease using small molecular compound
-
批准号:17209032
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$32.28万
-
财政年份:2005
-
负责人:SOBUE Gen
-
依托单位:
Development of pathogenesis-based therapy for polyglutamine diseases
-
批准号:17025020
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$106.94万
-
财政年份:2005
-
负责人:SOBUE Gen
-
依托单位:
Development of Pathogenesis-based treatment for spinal and bulbar muscular atrophy
-
批准号:15209031
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$32.28万
-
财政年份:2003
-
负责人:SOBUE Gen
-
依托单位:
Neurotrophin and their receptor mRNA expressions in neurodegenerative diseases.
-
批准号:06807059
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$0.83万
-
财政年份:1994
-
负责人:SOBUE Gen
-
依托单位:
GENE EXPRESSION AND REGULATION OF NEUROTROPHINS AND THEIR RECEPTORS IN PERIPHERAL NEUROPATHIES
-
批准号:02807085
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1990
-
负责人:SOBUE Gen
-
依托单位:
海外基金